gut microbiota metagenome sequencing for NSCLC patients received anti-PD-1 treatment
收藏NIAID Data Ecosystem2026-05-10 收录
官方服务：
资源简介：
Study goal: determine the gut bacterial species that were most prevalent and enriched in responders
应用场景：
创建时间：
2026-01-01
相关数据集
Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small Cell Lung Cancer
Tumor mutational burden (TMB) has emerged as a predictive biomarker of response to immune checkpoint inhibitors. Standardization of TMB measurement is essential for implementing diagnostic tools to gu
NIAID Data Ecosystem100
Additional file 13 of Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Supplementary Material 13: Table S1 DEG lists identified from NSCLC patients. Table S1a List of DEGs identified in unpaired comparison (all subjects), n = 927. Table S1b List of DEGs identified in pai
NIAID Data Ecosystem20
Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy
Background. Current clinical biomarkers for the PD-1 blockade therapy are insufficient because they rely only on the tumor properties such as PD-L1 expression frequency and the amount of tumor mutatio
NIAID Data Ecosystem10
Table_1_Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer.XLSX
Background: We hypothesized that non-small cell lung cancer (NSCLC) patients with a tumor positive for single nucleotide polymorphisms (SNPs) of the Excision Repair Cross Complementation Group 1 (ERCC
NIAID Data Ecosystem30
Metagenomic shotgun sequencing of gut microbiomes of melanoma patients receiving immune checkpoint inhibitor therapy. human gut metagenome
Metagenomic shotgun sequencing identifies specific human gut microbes that are associated with immune checkpoint therapy efficacy in melanoma patients
NIAID Data Ecosystem20
